Your Health, We Care
In clinical trials, Tazemetostat has shown significant anti-tumor activity. For example, in a clinical trial targeting patients with epithelioid sarcoma, Tazemetostat achieved an objective response rate (ORR) of 15% and a median overall survival (OS) of 82.4 months.
Tazemetostat has also been approved for the treatment of recurrent or refractory (R/R) follicular lymphoma (FL) patients with EZH2 mutations who have received at least two systemic therapies in the past, and has shown promising anti-tumor activity in other types of tumors.
